Close Menu

NEW YORK – Genetron Health, a Chinese cancer molecular profiling and sequencing technology company, said Thursday that it has received approval from the China National Medical Products Administration for a next-generation sequencing system and a kit for an eight-gene lung cancer panel.

The Genetron S2000 is a high-throughput, automated sequencer that can run two types of flow cells, with data output of 55 Gb to 1,440 Gb per run.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
08
Sponsored by
Qiagen

Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.